HD-OPM Archive
Topics › Cancer

Vitamin D receptor agonist plus chemotherapy proved safe in pancreatic cancer trial

Louis Nervegna · Jun 11, 2026 · ♥ 4 reactions · 0 comments · original Facebook post
CancerSupplements & vitamins
AI summary & key facts

Louis shares a report of a clinical trial combining a vitamin D receptor agonist with chemotherapy to break through the dense fibrotic matrix around pancreatic tumors. The headline finding is safety, and it is off-topic for heart disease.

Link to full article:

The ScientistPancreatic Cancer Chemotherapy Plus Vitamin D-Like Drug Proves Safe in Trial | The ScientistA vitamin D receptor agonist in combination with pancreatic cancer chemotherapy may help break the dense matrix surrounding tumors safely.the-scientist.com

Quoted:

One of the reasons pancreatic cancer is so difficult to treat doesn’t have to do with the tumor cells themselves but with the dense mesh of extracellular matrix surrounding them. In pancreatic cancer, fibroblasts become activated, leading to the production of this physical barrier that is thought to reduce the effectiveness of chemotherapy. This matrix also promotes an immunosuppressive environment around the tumors, preventing immune cells from attacking the cancer, allowing it to flourish.

However, an ingredient in sunshine may be the key to breaking through this dense fibrosis: vitamin D. Scientists have previously reported that activating the vitamin D receptor (VDR) in pancreatic fibroblasts while also administering chemotherapy could prevent fibrosis and extend survival in mouse models of pancreatic cancer.

Now, after more than a decade since this preclinical work, researchers have conducted the first clinical trial of a VDR agonist, called paricalcitol, in combination with chemotherapy in patients with metastatic pancreatic cancer. They found that the combination therapy was generally safe, and while the trial was not powered to test efficacy, the team noticed positive trends in patients who expressed VDR at higher levels compared to those who did not, suggesting a potential sub-group of patients for whom the treatment may work better.

“The data from this trial are very promising,” said Kenneth Olive, who studies pancreatic cancer at Columbia University Irving Medical Center and was not associated with the study. He explained that prior attempts to attack pancreatic cancer-associated fibroblasts have not extended survival times in clinical trials, but because paricalcitol acts differently from those other methods, it may prove more effective. “This is a pretty exciting moment for the entire field of pancreatic cancer researchers who study the tumor microenvironment as a means of going after the tumor,” he added.

Quoted:

Evans and Truitt are eager to move paricalcitol plus chemotherapy or another drug like daraxonrasib forward too. They are working on preclinical experiments with different combinations that will inform future clinical work. “The science supports that these fibroblastic responses that you see in pancreatic cancer really create this general therapeutic resistance, so there's nothing per se specific about chemotherapy for this,” Truitt said. Evans added, “There's been new studies with new therapies, and we think that the combination of the format that we have along with the newer therapeutics might synergize.”

#vitamindHD #paracalcitolHD #pancreaticcancerHD #cancerHD #danafarberHD #daraxonrasibHD #rasHD

Could the "sunshine vitamin" help chemotherapy beat pancreatic cancer tumors?

A new clinical trial shows that combining a vitamin D receptor agonist with standard chemotherapy may help it break through the physical barriers protecting pancreatic cancer tumors.

Read about the research via the link in the comments.

No photo description available.
← newer: First epigenetic reprogramming trial in the eye; cardiovascuolder: Low-dose lithium shows neuroprotective signals and lower dem →